InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
4
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by Levine James E., Chief Financial Officer. Insider active across 1 company, notably Cardiff Oncology, Inc.. In total, 4 filings have been published. Breakdown: 4 buys · 0 sell. Total volume traded: €112k. History available since 10 September 2021. The latest transaction was filed on 16 December 2024 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations4 total
2,564 shares@ US$3.838.3% of flowCommon StockSEC:0000950170-24-137938:0
Ideal exit: 12 Sept 2025 (T+270)
30,000 shares@ US$1.55741.7% of flowCommon StockSEC:0001628280-22-025099:0
Ideal exit: 13 Jun 2023 (T+270)
5,000 shares@ US$6.6225.0% of flowCommon StockSEC:0001628280-21-018433
Ideal exit: 7 Jun 2022 (T+270)
5,000 shares@ US$6.620.025% mcap50.0% of flowCommon StockSEC:0001628280-21-018433:0
Ideal exit: 7 Jun 2022 (T+270)
4 of 4 declarations
About Levine James E.
James E. Levine is the Chief Financial Officer at Cardiff Oncology, Inc. He is responsible for the financial management of the company, including financial planning and analysis. With a strong background in the healthcare sector, he contributes to Cardiff's mission of developing innovative treatments for patients.
